Jump to main content
Jump to site search

Issue 5, 2016
Previous Article Next Article

Discovery of serum metabolites for diagnosis of progression of mild cognitive impairment to Alzheimer's disease using an optimized metabolomics method

Author affiliations

Abstract

Mild cognitive impairment (MCI) is considered to represent early AD. Currently, there is a great need for sensitive tools to monitor the progression of MCI to AD. In this work, a nontargeted metabolomics approach was developed to examine metabolic differences in serum samples from the MCI subjects and the age-matched AD subjects. Based on principal component analysis, metabolic differences among AD and MCI subjects were identified. Nine metabolites in the serum of the AD subjects were significantly different from the MCI subjects. Two metabolites were selected as the candidate biomarkers and validated in separate and independent patient cohorts. The major contributors to the predictive model were upregulated sphinganine-1-phosphate and 7-ketocholesterol, which yielded satisfactory sensitivity, and specificity, indicating potential value for predicting the conversion of MCI to probable AD. The present study may provide a diagnosis tool to monitoring the progression of MCI to AD.

Graphical abstract: Discovery of serum metabolites for diagnosis of progression of mild cognitive impairment to Alzheimer's disease using an optimized metabolomics method

Back to tab navigation

Supplementary files

Article information


Submitted
19 Sep 2015
Accepted
22 Dec 2015
First published
05 Jan 2016

RSC Adv., 2016,6, 3586-3591
Article type
Communication
Author version available

Discovery of serum metabolites for diagnosis of progression of mild cognitive impairment to Alzheimer's disease using an optimized metabolomics method

Q. Liang, H. Liu, T. Zhang, Y. Jiang, H. Xing and A. Zhang, RSC Adv., 2016, 6, 3586
DOI: 10.1039/C5RA19349D

Social activity

Search articles by author

Spotlight

Advertisements